Triheptanoin improves brain energy metabolism in patients with Huntington disease - Test2 - elhamkhani - TriplyDB

Triheptanoin improves brain energy metabolism in patients with Huntington disease

Triheptanoin improves brain energy metabolism in patients with Huntington disease

http://www.wikidata.org/entity/Q28388261

about

Blood brain barrier: An overview on strategies in drug delivery, realistic in vitro modeling and in vivo live tracking In Vivo NMR Studies of the Brain with Hereditary or Acquired Metabolic Disorders.Triheptanoin Protects Motor Neurons and Delays the Onset of Motor Symptoms in a Mouse Model of Amyotrophic Lateral Sclerosis Triheptanoin dramatically reduces paroxysmal motor disorder in patients with GLUT1 deficiency Evolution of structural neuroimaging biomarkers in a series of adult patients with Niemann-Pick type C under treatment.Modification of Astrocyte Metabolism as an Approach to the Treatment of Epilepsy: Triheptanoin and Acetyl-L-Carnitine.Pridopidine for the treatment of Huntington's disease.Imaging and spectroscopic approaches to probe brain energy metabolism dysregulation in neurodegenerative diseases.Alternative Fuels in Epilepsy and Amyotrophic Lateral Sclerosis.Metabolic Dysfunctions in Amyotrophic Lateral Sclerosis Pathogenesis and Potential Metabolic Treatments Near-critical GLUT1 and Neurodegeneration.Triheptanoin: long-term effects in the very long-chain acyl-CoA dehydrogenase-deficient mouse.Glucose transportation in the brain and its impairment in Huntington disease: one more shade of the energetic metabolism failure?Triheptanoin for the treatment of brain energy deficit: A 14-year experience.A randomized, controlled, double-blind, crossover trial of triheptanoin in alternating hemiplegia of childhood.Towards an Understanding of Energy Impairment in Huntington's Disease Brain.A strategy for multimodal data integration: application to biomarkers identification in spinocerebellar ataxia.Triheptanoin protects against status epilepticus-induced hippocampal mitochondrial dysfunctions, oxidative stress and neuronal degeneration.A double-blind, placebo-controlled trial of triheptanoin in adult polyglucosan body disease and open-label, long-term outcome.Expanded neurochemical profile in the early stage of Huntington disease using proton magnetic resonance spectroscopy.Is visual activation associated with changes in cerebral high-energy phosphate levels?Metabolic perturbations associated with the consumption of a ketogenic medium-chain TAG diet in dogs with idiopathic epilepsy

P2860

Q28067855-487159DC-C1F5-46A2-ACE7-5845F4AAE576 Q31028468-C0662CDE-2577-467F-A042-D1A75EB990E3 Q36114275-D04D0803-41CD-4A19-8C13-B77ACACFD782 Q36859501-F46621A9-CF07-4EB8-A1D7-62498D23A1C7 Q37621074-65D9A2F3-7B6F-44AB-8A1D-FB52EA9B4696 Q38598388-28C3EA98-3C39-4661-9C14-023C4F6F931F Q38735562-89893552-5018-4AAC-88CE-489FB7B8E943 Q38918493-04F1176B-DA5B-462B-A3F4-19AC4B06A0A0 Q39014987-BE876E5C-3903-4900-A8E9-A14318D310B4 Q39101800-63F24D0D-9EDC-4DDB-ADF1-AA253ED982A9 Q39115052-888A0D44-0A29-4F87-A295-BF84D3D48AA0 Q39155516-5556AB58-55FE-4CB3-BC6F-683BD6817685 Q39233225-3BCBF254-AAED-4EED-BEDB-17C1E9986AF6 Q39422277-42112762-390F-4DE0-9C12-B0483B8A33B9 Q42284665-9C870BFE-977B-407E-9A12-8822455A50B5 Q47442924-0F03539F-FF2F-4D82-BE25-2A58B0666116 Q47652807-998FB103-DAFD-46C5-B5C5-F273B47D2DF8 Q47685527-D765A8E5-0A9C-4AC7-90D4-36799D78A8F4 Q47982921-F176091E-4C39-4FCB-A40C-BF2BE16867F9 Q48044131-5E447B9B-B3F9-4CE6-ADD3-7499668A7C0D Q53426946-0005543A-3C85-4332-BD2E-56950A084FFA Q57162761-6CF5D33D-3A35-4B1D-9ABD-891DB2528BD2

P2860

Triheptanoin improves brain energy metabolism in patients with Huntington disease

http://www.wikidata.org/entity/Q28388261

description

2015 nî lūn-bûn

@nan

2015 թուականի Փետրուարին հրատարակուած գիտական յօդուած

@hyw

2015 թվականի փետրվարին հրատարակված գիտական հոդված

@hy

2015年の論文

@ja

2015年論文

@yue

2015年論文

@zh-hant

2015年論文

@zh-hk

2015年論文

@zh-mo

2015年論文

@zh-tw

2015年论文

@wuu

name

Triheptanoin improves brain energy metabolism in patients with Huntington disease

@ast

Triheptanoin improves brain energy metabolism in patients with Huntington disease

@en

Triheptanoin improves brain energy metabolism in patients with Huntington disease

@nl

type

label

Triheptanoin improves brain energy metabolism in patients with Huntington disease

@ast

Triheptanoin improves brain energy metabolism in patients with Huntington disease

@en

Triheptanoin improves brain energy metabolism in patients with Huntington disease

@nl

prefLabel

Triheptanoin improves brain energy metabolism in patients with Huntington disease

@ast

Triheptanoin improves brain energy metabolism in patients with Huntington disease

@en

Triheptanoin improves brain energy metabolism in patients with Huntington disease

@nl

P1433

Q28388261-95B25459-9DDD-44EB-BB84-F1D43858E718

P1476

Q28388261-80D3EBB5-BFD9-46E1-856F-D6A6287266AD

P2093

Q28388261-240AACC2-3D8D-4468-A20D-D9D6F1FC5A88

Q28388261-3C1557FA-BEA7-4A63-9620-A47AC6CA2FE9

Q28388261-3FD45606-5F69-4ED8-ADBE-F372AD0F86D3

Q28388261-AD806AC6-12F2-4B0C-A292-50D15D825BF7

Q28388261-E7FC808D-03B6-485C-A350-E300211EBC19

P2860

Q28388261-0067FB97-5341-4390-9289-50EBA76E1782

Q28388261-07224FDC-E584-4337-8584-CC5DFE4AC582

Q28388261-21596020-06BC-486A-8694-3FD3EB3CA47A

Q28388261-298208C7-2125-4BEC-9C5B-2AE23D8DD512

Q28388261-3128C2F5-E5DC-428C-A6F0-F186A55DE18C

Q28388261-3C4116A3-9EDB-4E01-B75D-351BDAE54216

Q28388261-403E139F-A602-4FEC-852B-844A5E13730A

Q28388261-540A4F47-5551-4DFB-A2AB-7AFB1C52BE60

Q28388261-573F91A3-D325-48C2-807C-80C35C454D14

Q28388261-57F3FB01-1CA9-4966-8A7A-8034F2658798

P304

Q28388261-9C993876-355B-448F-875D-27FAD763D56C

P31

Q28388261-C67FCDE5-EFA4-492C-B668-6FFCBE73C5CD

P3181

Q28388261-AC92C599-848F-4508-97F8-9C39C2580B30

P356

Q28388261-B63EE84B-DA39-47A4-9A77-332F96DE48F5

P407

Q28388261-9DDEE144-17F1-46BB-80B9-73475D21A699

P433

Q28388261-8B6263F7-79D5-4074-9829-567BE3C36B34

P478

Q28388261-AF13E8BA-481E-4234-BDF3-A9AE9939A60B

P50

Q28388261-7F24B375-C60B-43F2-8962-EEB07B4FAD9D

Q28388261-F441B252-5EDD-47DC-B39A-D54A3D4CD1C5

P577

Q28388261-AECE0846-D233-44D3-AC06-BF0AC75567A0

P698

Q28388261-0C86F5E4-C849-480B-8FB6-4404AD30F361

P921

Q28388261-531FB2F7-3A81-4624-9542-2C99D0AB98F6

Q28388261-7585380D-0782-40E4-B795-F4DD4BABB232

P932

Q28388261-7BF02813-44E9-4D0E-9FCA-9A9765BE400E

P3181

P356

WNL.0000000000001214

P1433

P1476

Triheptanoin improves brain energy metabolism in patients with Huntington disease

@en

P2093

Daisy Rinaldi

http://www.w3.org/2001/XMLSchema#string

Fanny Mochel

http://www.w3.org/2001/XMLSchema#string

Isaac Mawusi Adanyeguh

http://www.w3.org/2001/XMLSchema#string

Pierre-Gilles Henry

http://www.w3.org/2001/XMLSchema#string

Samantha Caillet

http://www.w3.org/2001/XMLSchema#string

P2860

Huntington's disease: a clinical review.

Early alterations of brain cellular energy homeostasis in Huntington disease models

Striatal glucose metabolism and dopamine D2 receptor binding in asymptomatic gene carriers and patients with Huntington's disease

Carnitine palmitoyltransferase II deficiency: successful anaplerotic diet therapy.

Predictors of phenotypic progression and disease onset in premanifest and early-stage Huntington's disease in the TRACK-HD study: analysis of 36-month observational data.

Two-site reproducibility of cerebellar and brainstem neurochemical profiles with short-echo, single-voxel MRS at 3T.

Early energy deficit in Huntington disease: identification of a plasma biomarker traceable during disease progression.

Pyruvate carboxylase deficiency: clinical and biochemical response to anaplerotic diet therapy.

Potential endpoints for clinical trials in premanifest and early Huntington's disease in the TRACK-HD study: analysis of 24 month observational data.

The key role of anaplerosis and cataplerosis for citric acid cycle function.

P304

490-5

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P3181

3866978

http://www.w3.org/2001/XMLSchema#string

P356

10.1212/WNL.0000000000001214

http://www.w3.org/2001/XMLSchema#string

P407

P433

5

http://www.w3.org/2001/XMLSchema#string

P478

84

http://www.w3.org/2001/XMLSchema#string

P50

Romain Valabrégue

P577

2015-02-03T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

25568297

http://www.w3.org/2001/XMLSchema#string

P921

Huntington disease

P932

4336068

http://www.w3.org/2001/XMLSchema#string